Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-Ile359 allele as low-K(m) catalysts of cyclophosphamide and ifosfamide activation

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 211-221

  Chang, Thomas K H ^b   Yu, Li ^a   Goldstein, Joyce A ^c   Waxman, David J ^a  

^a USA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Anticancer drug activation; Cyclophosphamide; CYP2C; Ifosfamide

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 ISOENZYME; IFOSFAMIDE;

ALLELE; ARTICLE; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; METABOLIC ACTIVATION; PRIORITY JOURNAL;

7-ALKOXYCOUMARIN O-DEALKYLASE; ALLELES; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CATALYSIS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; IFOSFAMIDE; KINETICS; MIXED FUNCTION OXYGENASES; PHOSPHATIDYLCHOLINES; POLYMORPHISM, GENETIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030758131     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00006     Document Type: Article

References (66)

1. Aoyama T, Korzekwa K, Nagata K, Adesnik M, Reiss A, Lapenson DP, Gillette J, Gelboin HV, Waxman DJ, Gonzalez FJ. Sequence requirements for cytochrome P-450IIB1 catalytic activity. Alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine. J Biol Chem 1989: 264, 21327-21333.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995: 25, 261-270.
3. Benvenuto JA, Ayele W, Legha SS, Raber MN, Nicaise C, Newman RA. Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine. Anti-Cancer Drugs 1992: 3, 19-23.
4. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995: 29, 192-209.
5. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst 1992: 84, 1744-1748.
6. Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995: 31A, 69-76.
7. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneim-Forsch/Drug Res 1979: 29, 659-661.
8. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996: 60, 396-404.
9. Chang TKH, Waxman DJ. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res 1993: 53, 2490-2497.
10. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 1993: 53, 5629-5637.
11. Chang TKH, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997: 57, 1946-1954.
12. Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995: 55, 810-816.
13. Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 1979: 28, 2045-2049.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994a: 46, 594-598.
15. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994b: 269, 15419-15422.
16. Faber OK, Mouridsen HT, Skovsted L. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br J Clin Pharmacol 1975: 2, 281-285.
17. Faletto MB, Linko P, Goldstein JA. A single amino acid mutation (Ser 180>Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. J Biol Chem 1992: 267, 2032-2037.
18. Friedman HS, Colvin OM, Aisaka K, Popp J, Bossen EH, Reimer KA, Powell JB, Hilton J, Gross SS, Levi R, Bigner DD, Griffith OW. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 1990: 50, 2455-2462.
19. Furuya H, Meyer UA, Gelboin HV, Gonzalez FJ. Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol Pharmacol 1991: 40, 375-382.
20. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulant therapy. Pharmacogenetics 1995: 5, 389-392.
21. Ged C, Beaune P. Partial sequence and polymerase chain reaction-mediated analysis of expression of the human CYP2C18 gene. Pharmacogenetics 1992: 2, 109-115.
22. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988: 27, 6929-6940.
23. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994: 4, 285-299.
24. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994: 33, 1743-1752.
25. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992: 267, 83-90.
26. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996: 333, 447-458.
27. Halpert JR, He YA. Engineering of cytochrome P450 2B1 specificity. Conversion of an androgen 16 beta-hydroxylase to a 15 alpha-hydroxylase. J Biol Chem 1993: 268, 4453-4457.
28. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990: 46, 341-347.
29. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
30. Kimura S, Pastewka J, Gelboin HV, Gonzalez FJ. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res 1987: 15, 10053-10054.
31. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995: 40, 481-485.
32. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 753-759.
33. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993: 33, 36-42.
34. LeBlanc GA, Waxman DJ. Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res 1990: 50, 5720-5726.
35. Leo MA, Lasker JM, Raucy JL, Kim CI, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 1989: 269, 305-312.
36. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990: 30, 725-732.
37. Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ. The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 1991: 31, 77-82.
38. Lindberg RLP, Negishi M. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature 1989: 339, 632-634.
39. Masurel D, Houghton PJ, Young CL, Wainer IW. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. Canc Res 1990: 50, 252-255.
40. Meehan RR, Gosden JR, Rout D, Hastie ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, Sweeney J, Wolf CR. Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988: 42, 26-37.
41. Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 1990: 191, 437-444.
42. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996: 6, 1-42.
43. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995: 23, 154-158.
44. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964: 239, 2379-2385.
45. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994: 56, 471-476.
46. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
47. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
48. Schuler U, Waidelich P, Kolb H, Wagner T, Ehninger G. Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients. Eur J Clin Pharmacol 1991: 40, 521-523.
49. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
50. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988: 37, 301-355.
51. Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Report 1984: 68, 1247-1254.
52. Sladek NE, Smith PC, Bratt PM, Low JE, Powers JF, Borch RF, Coveney JR. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat Rep 1982: 66, 1889-1900.
53. Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991: 40, 69-79.
54. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human CYP2C9 locus. Pharmacogenetics 1996: 6, 429-439.
55. Sullivan TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996: 6, 341-349.
56. Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FP. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 1987: 26, 1094-1099.
57. Waxman DJ. Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J Biol Chem 1984: 259, 15481-15490.
58. Waxman DJ. Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods Enzymol 1991: 206, 249-267.
59. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P450. Purification and characterization of two closely related isozymic forms. J Biol Chem 1982: 257, 10446-10457.
60. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991: 290, 160-166.
61. Wrighton SA, Thomas PE, Willis P, Maines SL, Watkins PB, Levin W, Guzelian PS. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J Clin Invest 1987: 80, 1017-1022.
62. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993a: 306, 240-245.
63. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993b: 25, 453-484.
64. Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem (Tokyo) 1987: 102, 1075-1082.
65. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996: 41, 13-19.
66. Zhou HH, Anthony LB, Wood AJJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990: 30, 471-475.